Synthesis and SAR Studies of Novel Oxazolyl- and Thiazolyl-indoles and Their Intermediates as Selective Antiproliferative Agents Against HL-60 Leukemia and C6 Glioma Cell Lines.

IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL
ChemMedChem Pub Date : 2025-05-21 DOI:10.1002/cmdc.202500030
Patrik Pollák, Boglárka Szele, Máté Varga, Alexandra Paszternák, Kamilla Varga, András Dancsó, Gyula Simig, Balázs Volk, Tamás Tábi, Mátyás Milen
{"title":"Synthesis and SAR Studies of Novel Oxazolyl- and Thiazolyl-indoles and Their Intermediates as Selective Antiproliferative Agents Against HL-60 Leukemia and C6 Glioma Cell Lines.","authors":"Patrik Pollák, Boglárka Szele, Máté Varga, Alexandra Paszternák, Kamilla Varga, András Dancsó, Gyula Simig, Balázs Volk, Tamás Tábi, Mátyás Milen","doi":"10.1002/cmdc.202500030","DOIUrl":null,"url":null,"abstract":"<p><p>1,3-Oxazole-2-carboxamides, -carbothioamides and their 1,3-thiazole analogues coupled with indoles were synthesized with promising selective antitumor effects. All compounds were prepared from tryptamine derivatives in 3-5 reaction steps including a Robinson-Gabriel cyclization to construct the oxazole or thiazole ring. The pharmacological activities of the intermediates and target compounds were assessed. Our findings revealed several novel small molecules with cancer cell-specific antiproliferative and/or cytotoxic properties, tested on HL-60 leukemia and C6 glioma cell lines. The 3-heteroarylindole target compounds demonstrated greater effectiveness compared to their acyclic intermediates. Notably, only the sulfur-containing compounds, such as thiazoles and the intermediates containing an acyclic side chain with a carbothioamide group showed significant antiproliferative properties. This activity was further enhanced by adding an extra sulfur atom, either by replacing oxazole heterocycles with thiazoles or by modifying carboxamides into carbothioamides. Additionally, the presence of a chlorine substituent at position 5 of the indole ring improved both the potency and cancer selectivity of the compounds. The synthesized novel compounds and the reported synthetic methodologies present valuable tools for drug discovery aiming at emerging pharmacological targets in the field of oncology.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500030"},"PeriodicalIF":3.6000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202500030","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

1,3-Oxazole-2-carboxamides, -carbothioamides and their 1,3-thiazole analogues coupled with indoles were synthesized with promising selective antitumor effects. All compounds were prepared from tryptamine derivatives in 3-5 reaction steps including a Robinson-Gabriel cyclization to construct the oxazole or thiazole ring. The pharmacological activities of the intermediates and target compounds were assessed. Our findings revealed several novel small molecules with cancer cell-specific antiproliferative and/or cytotoxic properties, tested on HL-60 leukemia and C6 glioma cell lines. The 3-heteroarylindole target compounds demonstrated greater effectiveness compared to their acyclic intermediates. Notably, only the sulfur-containing compounds, such as thiazoles and the intermediates containing an acyclic side chain with a carbothioamide group showed significant antiproliferative properties. This activity was further enhanced by adding an extra sulfur atom, either by replacing oxazole heterocycles with thiazoles or by modifying carboxamides into carbothioamides. Additionally, the presence of a chlorine substituent at position 5 of the indole ring improved both the potency and cancer selectivity of the compounds. The synthesized novel compounds and the reported synthetic methodologies present valuable tools for drug discovery aiming at emerging pharmacological targets in the field of oncology.

新型恶唑和噻唑吲哚及其中间体选择性抗HL-60白血病和C6胶质瘤细胞的合成和SAR研究
合成了1,3-恶唑-2-羧酰胺、-碳硫酰胺及其与吲哚偶联的1,3-噻唑类似物,具有良好的选择性抗肿瘤作用。所有化合物均由色胺衍生物经过3-5个反应步骤制备而成,包括罗宾逊-加布里埃尔环以构建恶唑或噻唑环。对中间体和靶化合物的药理活性进行了评价。我们的发现揭示了几种具有癌细胞特异性抗增殖和/或细胞毒性的新型小分子,在HL-60白血病和C6胶质瘤细胞系上进行了测试。与无环中间体相比,3-杂芳基吲哚靶化合物表现出更大的有效性。值得注意的是,只有含硫化合物,如噻唑和含有碳硫酰胺基团的无环侧链的中间体显示出显著的抗增殖性能。通过添加一个额外的硫原子,或者用噻唑取代恶唑杂环,或者将羧酰胺修饰为碳硫酰胺,进一步增强了这种活性。此外,吲哚环第5位氯取代基的存在提高了化合物的效力和癌症选择性。合成的新化合物和报告的合成方法为肿瘤领域新兴药理靶点的药物发现提供了有价值的工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ChemMedChem
ChemMedChem 医学-药学
CiteScore
6.70
自引率
2.90%
发文量
280
审稿时长
1 months
期刊介绍: Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信